The Gree and Bennett Coleman & Co-backed education software provider boosted its series C round to $65m, with Tiger Global Management leading the deal.

Mastercard and Ally Ventures co-led a round which will support the credit card services provider's expansion, boosting its total funding to over $140m.

DNA Capital has returned to lead a $59.5m round for the Qualcomm Ventures-backed digital prescription startup.

BeiGene helped mRNA therapeutics developer Strand Therapeutics raise $52m while the Afterpay-backed AP Ventures led logistics provider Sendle's $35m series C round.

Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.

MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Sanofi Ventures co-led replacement therapy developer Glycomine's latest round, which included Novo, Asahi Kasei Pharma Ventures and Chiesi Ventures.

Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.

Sheng Ye Capital and existing investor So-Young participated in a round for the medical supplies ordering platform sized at a minimum of $70m.